Lantheus announced that CMS granted Transitional Pass-Through (TPT) payment status for its PYLARIFY TruVu injection, effective October 1, 2026. This designation allows for separate reimbursement in hospital outpatient settings, which is a significant positive for the product's market access and profitability.
Lantheus announced that its PYLARIFY TruVu injection has received Transitional Pass-Through (TPT) payment status from the Centers for Medicare & Medicaid Services (CMS), effective October 1, 2026. This is a crucial development because TPT status enables separate reimbursement for the diagnostic radiopharmaceutical in hospital outpatient settings, rather than being bundled into other payments. This significantly improves the economic viability and market access for PYLARIFY TruVu, directly benefiting Lantheus by increasing potential revenue and adoption among Medicare beneficiaries. For traders, this news is a clear positive catalyst for LNTH, as it de-risks the commercialization of a key product and provides a clear path to enhanced profitability, with long-term implications for the company's growth trajectory.